嵌合抗原受体T细胞治疗恶性血液病的研究进展

嵌合抗原受体(CAR)-T细胞治疗是一种新的免疫疗法.该方法是将识别肿瘤细胞相关抗原的受体与T细胞胞内信号域在体外进行基因重组,再将这些质粒转染至T细胞中,而这类表达CAR的T细胞可特异性识别具有靶抗原的肿瘤细胞并发挥杀伤作用.目前,CAR-T细胞在肿瘤治疗,尤其是在恶性血液病治疗上获得良好疗效,但其疗效、安全性、不良反应、质量控制方面均需进一步验证.笔者拟就CAR-T细胞治疗中的CAR设计、细胞制备、临床试验及不良反应进行综述.

Research progress of chimeric antigen receptor T cell therapy for malignant hematologic diseases

Chimeric antigen receptor (CAR)-T cell therapy is an emerging immunotherapy.Genes encoding fusion proteins of tumor cells antigen recognizing receptors and intracellular signaling domains of T cells recombined exr vivo,subsequently these plasmids were transfected into the T cells.Thus the T cells engineered to express a CAR could recognize special antigen on tumor cells and attack these cells.Currently CAR-T cell therapy showing striking effective in malignant tumor,especially in hematological malignancies,but the efficiency,safety,side effect,quality control of CAR-T cell therapy still need to be confirmed.In this review,we will introduce and discuss the CAR design,CAR-T cell manufacture,clinical trials and side effects in CAR-T cell therapy.